Evaluation of the safety and immunogenicity of GSK Bio's HPV vaccine 580299 when administered in healthy females aged 9-25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing.

Trial Profile

Evaluation of the safety and immunogenicity of GSK Bio's HPV vaccine 580299 when administered in healthy females aged 9-25 years using an alternative schedule and an alternative dosing as compared to the standard schedule and dosing.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Human papillomavirus vaccine recombinant bivalent Japan Vaccine/MedImmune (Primary) ; AS04B
  • Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 16 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Oct 2011 Planned end date changed from 1 Feb 2013 to 1 May 2013 as reported by ClinicalTrials.gov.
    • 11 Nov 2009 Planned end date changed from 1 Sep 2008 to 1 Feb 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top